Early research (Phase 1)Ended earlyNCT04990479What this trial is testingNous-PEV: a Novel Immunotherapy for Lung Cancer and MelanomaWho this might be right forMelanoma (Skin)Non-Small-Cell Lung Carcinoma Nouscom SRL 7
Early research (Phase 1)Study completedNCT00790010What this trial is testingBevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV MelanomaWho this might be right forMelanoma Dana-Farber Cancer Institute 46
Testing effectiveness (Phase 2)Study completedNCT02272855What this trial is testingCombination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic MelanomaWho this might be right forMalignant Melanoma Takara Bio Inc. 46
Large-scale testing (Phase 3)Study completedNCT01597908What this trial is testingDabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous MelanomaWho this might be right forMelanoma Novartis Pharmaceuticals 704
Testing effectiveness (Phase 2)Active Not RecruitingNCT04462406What this trial is testingUsing Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop TrialWho this might be right forAdvanced MelanomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+8 more ECOG-ACRIN Cancer Research Group 150
Testing effectiveness (Phase 2)Study completedNCT01726738What this trial is testingLCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional MutationsWho this might be right forStage III MelanomaStage IV MelanomaUnresectable Melanoma+1 more UNC Lineberger Comprehensive Cancer Center 17
Testing effectiveness (Phase 2)Ended earlyNCT02410863What this trial is testingBiopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced MelanomaWho this might be right forMalignant Melanoma Prof. Dr. med. Dirk Schadendorf 10
Early research (Phase 1)Active Not RecruitingNCT04007744What this trial is testingSonidegib and Pembrolizumab in Treating Patients With Advanced Solid TumorsWho this might be right forClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8+19 more Mayo Clinic 36
Large-scale testing (Phase 3)Active Not RecruitingNCT05732805What this trial is testingA Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic MelanomaWho this might be right forMelanomaMelanoma (Skin)Melanoma Stage III+4 more Biocad 270
Testing effectiveness (Phase 2)Study completedNCT03278665What this trial is testing4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 TherapyWho this might be right forMalignant Melanoma 4SC AG 40
Early research (Phase 1)Ended earlyNCT01067066What this trial is testingA Phase I Study of TPI 287 - Temozolomide Combination in MelanomaWho this might be right forMelanoma M.D. Anderson Cancer Center 21
Testing effectiveness (Phase 2)Ended earlyNCT02748564What this trial is testingAldesleukin and Pembrolizumab in Treating Patients With Stage III-IV MelanomaWho this might be right forMetastatic MelanomaStage III Mucosal Melanoma of the Head and NeckStage IIIA Skin Melanoma+6 more Rutgers, The State University of New Jersey 10
Testing effectiveness (Phase 2)Study completedNCT00072345What this trial is testingTemozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV MelanomaWho this might be right forIntraocular MelanomaMelanoma (Skin) Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Ended earlyNCT00272415What this trial is testingIntravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With MelanomaWho this might be right forMelanoma Genentech, Inc. 39
Early research (Phase 1)Study completedNCT01672450What this trial is testingIntratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV MelanomaWho this might be right forMelanoma University of Utah 12
Testing effectiveness (Phase 2)Study completedNCT00612664What this trial is testingPhase II, 2nd Line Melanoma - RAND MonotherapyWho this might be right forMelanoma Bristol-Myers Squibb 158
Testing effectiveness (Phase 2)Study completedNCT01136967What this trial is testingAn Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV MelanomaWho this might be right forUnresectable Stage IIIStage IV Melanoma Eisai Inc. 182
Not applicableStudy completedNCT00477919What this trial is testingE-MOSAIC Electronic Tool to Monitor SymptomsWho this might be right forCancer Swiss Cancer Institute 264
Testing effectiveness (Phase 2)Study completedNCT04570332What this trial is testingBO-112 With Pembrolizumab in Unresectable Malignant MelanomaWho this might be right forMelanoma Highlight Therapeutics 42
Early research (Phase 1)Study completedNCT01176461What this trial is testingMultiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558Who this might be right forMelanoma (Skin) H. Lee Moffitt Cancer Center and Research Institute 127